Daily Market Updates: Moderna and Merck cancer vaccine combo extends time without melanoma return

Earnings

Home›Earnings›Previews›Moderna and Merck cancer vaccine combo extends time wi…

Moderna and Merck cancer vaccine combo extends time without melanoma return

The companies said their late-stage regimen improved outcomes versus Keytruda alone, helping drive Moderna shares up 50%.

Reported · Written up by our desk · Previews

CNBC Markets reports that Moderna and Merck’s cancer vaccine combination showed promise in a late-stage trial, with the companies saying the regimen significantly extended the time patients lived without their melanoma returning compared with Merck’s Keytruda alone.

The outlet added that the news sent Moderna’s stock up about 50% on the reaction to the trial results.

← Newer storyRipple raises $275M to expand into prime brokerage and clearing Older story →Bitcoin holds near $64,000 as bond yields surge and Fed odds shift

More like this

EarningsAnalog Devices forecasts stronger Q4 after beating fiscal Q3 estimates

EarningsLowe's warns of ongoing pressure in home improvement spending

EarningsCibus unit Interoc expands rice trait testing, revenue rises

EarningsIntuitive Machines rallies after winning $600 million communications program

EarningsSpace Exploration Technologies targets $100 billion annual revenue by December

Sources

CNBC MarketsModerna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 50%

CNBC WorldModerna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 50%

Earnings

Moderna and Merck cancer vaccine combo extends time without melanoma return

More like this

Sources

Get the close, explained.